Advertisement
Screener

vTv Therapeutics Inc. (VTVT) Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount

2.0 / 5 stars · 28/71 Roast Me

vTv Therapeutics Inc. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount

vTv Therapeutics Inc. (VTVT) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2026-03-10

  • vTv Therapeutics Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2024-12-31 was $0.00.
  • vTv Therapeutics Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2023-12-31 was $0.00.
  • vTv Therapeutics Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2023-09-30 was $4.20M.
  • vTv Therapeutics Inc. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2022-12-31 was $0.00.
  • vTv Therapeutics Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2025 was $0.00.
  • vTv Therapeutics Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
  • vTv Therapeutics Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $4.25M.
  • vTv Therapeutics Inc. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2022 was $0.00.
Period endEquity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 monthEquity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 6 monthEquity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 9 monthEquity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month
2025-12-31$0.00
10-K · filed 2026-03-10
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10
$0.00
10-K · filed 2026-03-10
2024-09-30$0.00
10-Q · filed 2024-11-12
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10
$4.20M
derived: sum of 2 quarters · filed 2026-03-10
$4.25M
10-K · filed 2026-03-10
2023-09-30$4.20M
10-Q · filed 2023-11-09
$4.25M
10-Q · filed 2024-11-12
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20
$0.00
10-K · filed 2025-03-20
2022-09-30$0.00
10-Q · filed 2023-11-09
2021-12-31$0.00
10-K · filed 2024-03-13